Q2 26 EPS
$3.65
BEAT +1.15%
Est. $3.61
Q2 26 Revenue
$16.99B
BEAT +1.40%
Est. $16.76B
vs S&P Since Q2 26
-8.8%
TRAILING MARKET
ABBV -5.5% vs S&P +3.3%
Market Reaction
Did ABBV Beat Earnings? Q2 2026 Results
AbbVie delivered a solid second quarter in 2026, beating consensus on both the top and bottom lines as its immunology franchise continued to carry the growth story. Adjusted diluted EPS came in at $3.65, clearing the $3.08 consensus estimate by 1.15%… Read more AbbVie delivered a solid second quarter in 2026, beating consensus on both the top and bottom lines as its immunology franchise continued to carry the growth story. Adjusted diluted EPS came in at $3.65, clearing the $3.08 consensus estimate by 1.15%, while total net revenues of $16.99 billion topped the $16.76 billion consensus by 1.40% and rose 10.2% year over year. The primary engine behind the outperformance was immunology, where Skyrizi and Rinvoq posted revenue growth of 24.4% and 24.5% respectively, more than absorbing Humira's continued biosimilar erosion to $756 million. Neuroscience added further lift, growing 20.3% to $3.23 billion on the strength of Vraylar and Botox Therapeutic. Looking ahead, AbbVie trimmed its full-year 2026 adjusted EPS guidance range by $0.04 at the midpoint to $13.87 to $14.07, reflecting $0.14 of dilution from its pending $10.90 billion acquisition of Apogee Therapeutics, partially offset by $0.10 of operational overperformance, as the company continues broadening its immunology pipeline ahead of long-term Humira replacement needs.
Key Takeaways
- • Skyrizi net revenues grew 24.4% to $5.505 billion, driven by strong demand across indications
- • Rinvoq net revenues grew 24.5% to $2.525 billion with continued market penetration
- • Neuroscience portfolio grew 20.3% led by Vraylar, Botox Therapeutic, and migraine franchise expansion
- • Vyalev contributed $256 million as a new growth driver in Parkinson's disease
- • Adjusted tax rate declined to 14.7% from 16.2% year over year
- • Acquired IPR&D and milestones expense was $291 million in Q2 2026 vs. $823 million in Q2 2025
ABBV Forward Guidance & Outlook
AbbVie updated its full-year 2026 adjusted diluted EPS guidance range from $13.91–$14.11 to $13.87–$14.07, a reduction of $0.04 at the midpoint. The update reflects $0.14 of dilution from the proposed Apogee Therapeutics acquisition (expected to close in Q3 2026), partially offset by $0.10 of operational overperformance. The guidance includes $0.58 per share of unfavorable acquired IPR&D and milestones expense incurred year-to-date through Q2 2026, and excludes any such expense that may be incurred beyond Q2 as it cannot be reliably forecasted.
ABBV YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
ABBV Revenue by Segment
With YoY comparisons, source: SEC Filings
ABBV Revenue by Geography
With YoY comparisons, source: SEC Filings
“AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value.”
— Robert A. Michael, Q2 2026 Earnings Press Release
ABBV Earnings Trends
ABBV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABBV EPS Trend
Earnings per share: estimate vs actual
ABBV Revenue Trend
Quarterly revenue: estimate vs actual
ABBV Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $3.61 | $3.65 | +1.15% | $16.99B | +1.40% |
| Q1 26 MISS | $2.67 | $2.65 | -0.66% | $15.00B | +1.93% |
| Q4 25 BEAT FY | $2.65 | $2.71 | +2.16% | $16.62B | +1.23% |
| FY Full Year | $9.94 | $10.00 | +0.64% | $61.16B | +0.33% |
| Q3 25 BEAT | $1.78 | $1.86 | +4.23% | $15.78B | +1.23% |
| Q2 25 BEAT | $2.91 | $2.97 | +2.14% | $15.42B | +2.61% |
| Q1 25 BEAT | $2.40 | $2.46 | +2.62% | $13.34B | +3.27% |